))
Episode 49: Jeffrey Bacha - Chairman, Rakovina Therapeutics
Manage episode 390452725 series 3526490
Innhold levert av Vial. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Vial eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Join Jeffrey Bacha, a pioneer in the fight against cancer and the creative force behind Rakovina Therapeutics. For 25 years, Jeffrey has been reshaping the industry landscape, and today, he gives us a peek into his world of innovation. We venture into Rakovina's research and development of oncology drugs. exploring their groundbreaking technique combining PARP and HDAC inhibitors into a single molecule, a game-changer in enhancing synergy and reducing toxicity.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to catie@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Kapitler
1. Episode 49: Jeffrey Bacha - Chairman, Rakovina Therapeutics (00:00:00)
2. Redefining Cancer Treatment (00:00:07)
3. Advancements in Oncology Drug Development (00:12:09)
62 episoder
Del
